| Literature DB >> 34307184 |
Yangyang Li1, Yiming Zhang1, Kongxi Wei1, Jinpeng He2, Nan Ding2, Junrui Hua2, Ting Zhou1, Fan Niu1, Gucheng Zhou1, Tongfan Shi1, Liying Zhang1,3, Yongqi Liu1,4.
Abstract
Gut microbiota is regarded as the second human genome and forgotten organ, which is symbiotic with the human host and cannot live and exist alone. The gut microbiota performs multiple physiological functions and plays a pivotal role in host health and intestinal homeostasis. However, the gut microbiota can always be affected by various factors and among them, it is radiotherapy that results in gut microbiota dysbiosis and it is often embodied in a decrease in the abundance and diversity of gut microbiota, an increase in harmful bacteria and a decrease in beneficial bacteria, thereby affecting many disease states, especially intestine diseases. Furthermore, gut microbiota can produce a variety of metabolites, among which short-chain fatty acids (SCFAs) are one of the most abundant and important metabolites. More importantly, SCFAs can be identified as second messengers to promote signal transduction and affect the occurrence and development of diseases. Radiotherapy can lead to the alterations of SCFAs-producing bacteria and cause changes in SCFAs, which is associated with a variety of diseases such as radiation-induced intestinal injury. However, the specific mechanism of its occurrence is not yet clear. Therefore, this review intends to emphasize the alterations of gut microbiota after radiotherapy and highlight the alterations of SCFAs-producing bacteria and SCFAs to explore the mechanisms of radiation-induced intestinal injury from the perspective of gut microbiota and its metabolite SCFAs.Entities:
Keywords: SCFAs; dysbiosis; gut microbiota; metabolites; radiation-induced intestinal injury; radiotherapy
Year: 2021 PMID: 34307184 PMCID: PMC8300561 DOI: 10.3389/fcimb.2021.577236
Source DB: PubMed Journal: Front Cell Infect Microbiol ISSN: 2235-2988 Impact factor: 5.293
Radiotherapy causes gut microbiota dysbiosis.
| Model | Sample type | Sequencing Method | Gut microbiota dysbiosis | Reference |
|---|---|---|---|---|
| Male Wistar rats | Fecal samples | Microarray (16S rRNA) and quantitative PCR analyses | Increase: 12 members of | ( |
| Decrease: the levels of 47 | ||||
| nine gynecologic cancer patients | Fecal samples | Pyrosequencing of bacterial 16S rRNA fragments | Increase: | ( |
| Decrease: the number and abundance, | ||||
| C57BL/6 mice | the contents of the small and large intestines | Illumina MiSeq high-throughput sequencing and bacterial 16S rRNA | Increase: | ( |
| Decrease: | ||||
| C57BL/6J mice | Fecal samples | 16S rRNA sequencing and metabolomics | Increase: | ( |
| Decrease : | ||||
| Gottingen minipigs (GMP) and Chinese rhesus macaques | Fecal samples | Illumina MiSeq sequencing and 16S rRNA amplicon | Increase:intracellular symbionts ( | ( |
| Decrease: | ||||
| 137 bank voles | Fecal samples | amplicon sequencing of bacterial 16S rRNA genes | Increase: | ( |
| Male BALB/c mice | Fecal samples | high-throughput sequencing of 16S rRNA | Increase : | ( |
| Decrease: | ||||
| Patients with and without radiation enteropathy | Fecal samples, intestinal mucosa samples | Metataxonomics (16S rRNA gene) and imputed metataxonomics (Piphillin) | Increase: | ( |
| Decrease: bacterial diversity | ||||
| 18 cervical cancer patients | Fecal samples | 16S rRNA sequencing using the Illumina HiSeq platform | Increase: β‐diversity, | ( |
| Decrease: α‐diversity, |
The production of SCFAs and changes after radiotherapy.
| SCFAs | Producing bacteria | Biosynthetic pathway | Radiotherapy causes changes in SCFAs | Reference |
|---|---|---|---|---|
| Acetate | many enteric bacteria, such as | pyruvate in acetyl-CoA pathway | Decrease of SCFAs | ( |
|
| Wood-Ljungdahl Pathway | ( | ||
| Propionate |
| succinate pathway | Decrease of SCFAs | ( |
| some | acrylate pathway | |||
|
| propanediol pathway | |||
| butyrate |
| butyryl-CoA:acetate CoA-transferase route | Decrease of SCFAs | ( |
|
| phospho-transbutyrylase and butyrate kinase |
Figure 1Mechanism of SCFAs on radiation-induced intestinal injury. Radiotherapy can lead to dysbiosis of the gut microbiota, including the changes in SCFAs-producing bacteria. The bacteria producing acetate, propionate and butyrate are all reduced, and the ability to produce SCFAs is weakened accordingly. SCFAs mainly induce downstream reactions through two pathways: activation of GPCRs and inhibition of HDAC. After activating GPCRs, SCFAs can act on downstream MAPK, NF-κB, PI3K/AKT, JAK/STAT, Wnt/β-catenin and other signaling pathways to promote signal transduction. SCFAs production is reduced and its anti-inflammatory activity is weakened, which in turn promotes the release of inflammatory cytokines and triggers inflammatory response. In addition, reduced production of SCFAs also induces TGF-β mediated intestinal fibrosis. Inflammation and intestinal fibrosis are two different outcomes of acute and chronic radiation-induced intestinal injury. Black arrows indicate promotion, and black lines indicate inhibition.
Figure 2The relationship between ionizing radiation, gut microbiota, SCFAs and radiation-induced intestinal injury. Ionizing radiation can lead to dysbiosis of gut microbiota, which is mainly disruption and it leads to the decrease of beneficial bacteria and increase in harmful or pathogenic bacteria. Gut microbiota dysbiosis includes the decrease in SCFAs-producing bacteria, which may result in the decrease of SCFAs. The decrease of SCFAs may be a major pathogenesis of radiation-induced intestinal injury.